NEO
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
NeoGenomics, Inc.
- Nom
- NeoGenomics, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Diagnostics & Research
- Bourse
- NASDAQ
- Capitalisation
- $2.2B
- Employés
- 2,500
- PDG
- Anthony Zook
- Site web
- https://www.neogenomics.com
- Marché
- BDSXCSTLFRNMGHGRALMYGN
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$321,400
Avg sell (VWAP, 90d window) $16.07 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-04 | Aunan Greg D | Sell · S | 20,000 | $16.07 | $321,400 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-08-07 | Gilbert Cisneros | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-08-07 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-05-07 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2021-12-30 | Deborah K. Ross | Purchase | $15,001 - $50,000 |
| 2021-11-09 | Bob Gibbs | Sale (Full) | $1,001 - $15,000 |
| 2020-03-02 | Dwight Evans | Purchase | $1,001 - $15,000 |
| 2019-12-19 | Bob Gibbs | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
NEO presents a deeply concerning financial profile with chronic losses, negative FCF, and a dangerously negative interest coverage ratio that signals high long-term insolvency risk.
The first sentence of the analysis written for NEO on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 4.26 · operating margin -9.1% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 38.8% | 43.9% | 41.3% | 36.9% | 38.6% | |
| Ebit Margin | -14.6% | -11.2% | -15.2% | -29.8% | -1.4% | |
| Ebitda Margin | -5.3% | -0.2% | -3.0% | -16.2% | 9.6% | |
| Operating Profit Margin | -9.1% | -13.9% | -18.2% | -30.9% | -24.5% | |
| Pretax Profit Margin | -15.2% | -12.2% | -16.4% | -31.3% | -3.1% | |
| Continuous Operations Profit Margin | -14.9% | -11.9% | -14.9% | -28.3% | -1.7% | |
| Net Profit Margin | -14.9% | -11.9% | -14.9% | -28.3% | -1.7% | |
| Bottom Line Profit Margin | -14.9% | -11.9% | -14.9% | -28.3% | -1.7% | |
| Current Ratio | 4.261 | 1.979 | 6.197 | 6.731 | 7.813 | |
| Quick Ratio | 3.938 | 1.890 | 5.946 | 6.461 | 7.544 | |
| Solvency Ratio | -0.077 | -0.008 | -0.021 | -0.101 | 0.059 | |
| Cash Ratio | 1.808 | 1.218 | 3.556 | 2.926 | 3.632 | |
| Price To Earnings Ratio | -2.800 | -5.316 | -4.623 | -1.593 | -98.046 | |
| Price To Earnings Growth Ratio | -0.079 | 0.465 | 0.117 | -0.001 | 0.349 | |
| Forward Price To Earnings Growth Ratio | -0.079 | 0.465 | 0.117 | -0.001 | 0.349 | |
| Price To Earnings Diluted Ratio | -2.800 | -5.316 | -4.623 | -1.593 | -98.046 | |
| Price To Earnings Diluted Growth Ratio | -0.079 | 0.465 | 0.117 | -0.001 | 0.342 | |
| Price To Book Ratio | 0.360 | 0.463 | 0.431 | 0.230 | 0.739 | |
| Price To Sales Ratio | 0.414 | 0.632 | 0.686 | 0.450 | 1.690 | |
| Price To Free Cash Flow Ratio | -13.835 | -12.265 | -13.227 | -2.369 | -9.009 | |
| Price To Operating Cash Flow Ratio | 57.609 | 59.443 | -207.949 | -3.478 | -30.634 | |
| Debt To Assets Ratio | 0.347 | 0.370 | 0.364 | 0.351 | 0.328 | |
| Debt To Equity Ratio | 0.565 | 0.671 | 0.650 | 0.612 | 0.553 | |
| Debt To Capital Ratio | 0.361 | 0.402 | 0.394 | 0.380 | 0.356 | |
| Long Term Debt To Capital Ratio | 0.326 | 0.274 | 0.364 | 0.349 | 0.325 | |
| Financial Leverage Ratio | 1.625 | 1.815 | 1.786 | 1.743 | 1.687 | |
| Working Capital Turnover Ratio | 2.496 | 1.661 | 1.165 | 0.919 | 0.999 | |
| Operating Cash Flow Ratio | 0.059 | 0.023 | -0.020 | -0.734 | -0.306 | |
| Operating Cash Flow Sales Ratio | 0.007 | 0.011 | -0.003 | -0.129 | -0.055 | |
| Free Cash Flow Operating Cash Flow Ratio | -4.164 | -4.847 | 15.722 | 1.468 | 3.400 | |
| Debt Service Coverage Ratio | -4.273 | 0.002 | -1.227 | -8.869 | 5.689 | |
| Interest Coverage Ratio | -17.607 | -13.920 | -15.598 | -20.792 | -14.447 | |
| Short Term Operating Cash Flow Coverage Ratio | 1.095 | 0.035 | 0.000 | 0.000 | -23.544 | |
| Operating Cash Flow Coverage Ratio | 0.011 | 0.012 | -0.003 | -0.108 | -0.044 | |
| Capital Expenditure Coverage Ratio | 0.194 | 0.171 | -0.068 | -2.136 | -0.417 | |
| Dividend Paid And Capex Coverage Ratio | 0.194 | 0.171 | -0.068 | -2.136 | -0.417 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -15.868 | -434.008 | -38.355 | -7.012 | 23.971 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 38.9% | ▼-5.1% | ▼-1.1% |
| Ebit Margin | -14.6% | ▼-3.4% | ▼-0.2% |
| Ebitda Margin | -5.3% | ▼-5.1% | ▼-2.3% |
| Operating Profit Margin | -9.1% | ▲4.9% | ▲10.2% |
| Pretax Profit Margin | -15.2% | ▼-2.9% | ▲0.5% |
| Continuous Operations Profit Margin | -14.8% | ▼-2.9% | ▼-0.5% |
| Net Profit Margin | -14.8% | ▼-2.9% | ▼-0.5% |
| Bottom Line Profit Margin | -14.8% | ▼-2.9% | ▼-0.5% |
| Current Ratio | 4.261 | ▲2.283 | ▼-1.135 |
| Quick Ratio | 3.938 | ▲2.048 | ▼-1.218 |
| Solvency Ratio | -0.077 | ▼-0.068 | ▼-0.047 |
| Cash Ratio | 1.808 | ▲0.589 | ▼-0.821 |
| Price To Earnings Ratio | -2.800 | ▲2.516 | ▲19.676 |
| Price To Earnings Growth Ratio | -0.079 | ▼-0.544 | ▼-0.249 |
| Forward Price To Earnings Growth Ratio | -0.079 | ▼-0.544 | ▼-0.249 |
| Price To Earnings Diluted Ratio | -2.800 | ▲2.516 | ▲19.676 |
| Price To Earnings Diluted Growth Ratio | -0.079 | ▼-0.544 | ▼-0.248 |
| Price To Book Ratio | 0.360 | ▼-0.102 | ▼-0.084 |
| Price To Sales Ratio | 0.414 | ▼-0.218 | ▼-0.360 |
| Price To Free Cash Flow Ratio | -13.835 | ▼-1.570 | ▼-3.694 |
| Price To Operating Cash Flow Ratio | 57.609 | ▼-1.834 | ▲82.611 |
| Debt To Assets Ratio | 0.347 | ▼-0.022 | ▼-0.005 |
| Debt To Equity Ratio | 0.565 | ▼-0.106 | ▼-0.045 |
| Debt To Capital Ratio | 0.361 | ▼-0.041 | ▼-0.018 |
| Long Term Debt To Capital Ratio | 0.326 | ▲0.052 | ▼-0.001 |
| Financial Leverage Ratio | 1.625 | ▼-0.190 | ▼-0.106 |
| Working Capital Turnover Ratio | 2.496 | ▲0.835 | ▲1.048 |
| Operating Cash Flow Ratio | 0.059 | ▲0.036 | ▲0.255 |
| Operating Cash Flow Sales Ratio | 0.007 | ▼-0.003 | ▲0.041 |
| Free Cash Flow Operating Cash Flow Ratio | -4.164 | ▲0.683 | ▼-6.480 |
| Debt Service Coverage Ratio | -4.273 | ▼-4.276 | ▼-2.538 |
| Interest Coverage Ratio | -17.607 | ▼-3.687 | ▼-1.134 |
| Short Term Operating Cash Flow Coverage Ratio | 1.095 | ▲1.060 | ▲5.578 |
| Operating Cash Flow Coverage Ratio | 0.011 | ▼-0.001 | ▲0.037 |
| Capital Expenditure Coverage Ratio | 0.194 | ▲0.023 | ▲0.645 |
| Dividend Paid And Capex Coverage Ratio | 0.194 | ▲0.023 | ▲0.645 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -15.868 | ▲418.140 | ▲78.386 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $301.3M | $417.5M | $406.1M | $229.6M | $818.6M | |
| Enterprise value | $614.0M | $655.8M | $675.3M | $577.3M | $1.11B | |
| EV / Sales | 0.84x | 0.99x | 1.14x | 1.13x | 2.30x | |
| EV / Op. cash flow | 117.39x | 93.38x | -345.78x | -8.75x | -41.71x | |
| EV / Free cash flow | -28.19x | -19.27x | -21.99x | -5.96x | -12.27x | |
| EV / EBITDA | -15.87x | -434.01x | -38.35x | -7.01x | 23.97x | |
| Net debt / EBITDA | -8.08x | -157.72x | -15.29x | -4.22x | 6.37x | |
| Current ratio | 4.26x | 1.98x | 6.20x | 6.73x | 7.81x | |
| Income quality | -0.05x | -0.09x | 0.02x | 0.46x | 3.20x | |
| Graham net-net | -$9 | -$9 | -$9 | -$8 | -$6 | |
| Tax burden | 98.0% | 97.6% | 90.6% | 90.5% | 55.4% | |
| Interest burden | 103.5% | 108.9% | 107.7% | 105.0% | 219.9% | |
| Working capital | $288.0M | $294.8M | $500.5M | $515.4M | $594.3M | |
| Invested capital | $1.26B | $1.33B | $1.58B | $1.64B | $1.78B | |
| Return on assets | -7.9% | -4.8% | -5.2% | -8.3% | -0.4% | |
| Operating ROA | -4.4% | -5.5% | -6.3% | -8.7% | -8.3% | |
| Return on tangible assets | -19.7% | -10.2% | -11.2% | -17.8% | -0.9% | |
| Return on equity | -12.9% | -8.7% | -9.3% | -14.5% | -0.8% | |
| Return on invested capital | -5.1% | -5.8% | -6.1% | -8.6% | -3.7% | |
| Return on capital employed | -5.2% | -6.9% | -6.8% | -9.6% | -6.7% | |
| Earnings yield | -35.9% | -18.9% | -21.7% | -62.8% | -1.0% | |
| Free cash flow yield | -7.2% | -8.2% | -7.6% | -42.2% | -11.1% | |
| Capex / Op. cash flow | 516.4% | 584.7% | -1472.2% | -46.8% | -240.0% | |
| Capex / Depreciation | 39.8% | 56.6% | 39.6% | 44.5% | 120.2% | |
| Capex / Sales | 3.7% | 6.2% | 4.9% | 6.1% | 13.2% | |
| SG&A / Sales | 50.2% | 47.0% | 47.3% | 54.5% | 58.6% | |
| R&D / Sales | 5.1% | 4.7% | 4.6% | 5.9% | 4.5% | |
| Stock comp / Sales | 5.7% | 5.1% | 4.2% | 4.8% | 4.6% | |
| Intangibles / Total assets | 59.6% | 52.7% | 53.3% | 53.5% | 51.8% | |
| Days sales outstanding | 80d | 83d | 81d | 86d | 85d | |
| Days payables outstanding | 19d | 21d | 21d | 23d | 22d | |
| Operating cycle | 103d | 110d | 106d | 113d | 113d | |
| Cash conversion cycle | 84d | 88d | 85d | 90d | 91d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-05 NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its executive leadership and board of directors succession plan.
- 2026-09-28 NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212 CALABASAS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on November 17, 2026, for an in-person End-of-Phase 1 Type B meeting concerning NEO212.
- 2026-09-26 Omada Health (NASDAQ:OMDA) and NeoGenomics (NASDAQ:NEO) Head-To-Head Contrast NeoGenomics (NASDAQ: NEO - Get Free Report) and Omada Health (NASDAQ: OMDA - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends. Risk and Volatility NeoGenomics has a beta of 1.75,
- 2026-09-21 NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference NeoGenomics (NASDAQ: NEO) executives outlined the company''s strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease testing and workflow tools designed for physicians treating patients closer to home. Speaking at the Morgan Stanley Healthcare Conference, Chief Executive Officer Tony Zook said the company remains focused exclusively on oncology
- 2026-09-20 NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference NeoGenomics NASDAQ: NEO executives outlined the company''s strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease testing and workflow tools designed for physicians treating patients closer to home.
- 2026-09-16 NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results CALABASAS, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that Executive Chairman, President and Chief Executive Officer Amir F.
- 2026-09-10 Which Is the Better Healthcare ETF: Fidelity''s Low-Cost FHLC or First Trust''s High-Conviction FBT? One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.
- 2026-09-09 NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is entering a potentially important new phase with fresh institutional capital, encouraging Phase 2a data and a string of open-market insider purchases.
- 2026-09-01 NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that the Company will parti
- 2026-09-01 NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, Sept. 14–16, 2026, in New York.